Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QLT, a biotechnology company engaged in the development and commercialisation of therapies for the eye, has reported revenues of $8.59m for the third quarter ended 30 September 2010, a decrease of 2.3%, compared to $8.79m for the same period in 2009.
Subscribe to our email newsletter
QLT has posted a net loss of $697,000 for the third quarter 2010, or $0.01 loss per diluted share, compared to net income of $8.92m, or $0.04 per diluted share, for the comparable period in 2009.
Operating loss was $7.05m, compared to $5.98m for the comparable period in 2009.
QLT has posted a revenue of $34.68m, for the nine months ended 30 September 2010, compared to $31.3m for the year ago period.
For the nine months ended 30 September 2010, QLT has posted a net income of $1.69m, or $0.03 per diluted share, compared to $18.85m, or $0 per diluted share, for the year ago period.
Operating loss was $16.07m, compared to $15.93m for the year ago period.